> Detailanzeige

Daruwalla, Cyrus; Shaygannejad, Vahid; Ozakbas, Serkan; Havrdova, Eva Kubala; Horakova, Dana; Alroughani, Raed; Boz, Cavit; Patti, Francesco; Onofrj, Marco; Lugaresi, Alessandra; Eichau, Sara; Girard, Marc; Prat, Alexandre; Duquette, Pierre; Yamout, Bassem; Khoury, Samia J; Sajedi, Seyed Aidin; Turkoglu, Recai; Altintas, Ayse; Skibina, Olga; Buzzard, Katherine; Grammond, Pierre; Karabudak, Rana; van der Walt, Anneke; [...]

Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
  • Beteiligte: Daruwalla, Cyrus; Shaygannejad, Vahid; Ozakbas, Serkan; Havrdova, Eva Kubala; Horakova, Dana; Alroughani, Raed; Boz, Cavit; Patti, Francesco; Onofrj, Marco; Lugaresi, Alessandra; Eichau, Sara; Girard, Marc; Prat, Alexandre; Duquette, Pierre; Yamout, Bassem; Khoury, Samia J; Sajedi, Seyed Aidin; Turkoglu, Recai; Altintas, Ayse; Skibina, Olga; Buzzard, Katherine; Grammond, Pierre; Karabudak, Rana; van der Walt, Anneke; [...]
  • Erschienen: SAGE Publications, 2023
  • Erschienen in: Multiple Sclerosis Journal
  • Sprache: Englisch
  • DOI: 10.1177/13524585231151951
  • ISSN: 1352-4585; 1477-0970
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec><jats:title>Background:</jats:title><jats:p> The prognostic significance of non-disabling relapses in people with relapsing-remitting multiple sclerosis (RRMS) is unclear. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To determine whether early non-disabling relapses predict disability accumulation in RRMS. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> We redefined mild relapses in MSBase as ‘non-disabling’, and moderate or severe relapses as ‘disabling’. We used mixed-effects Cox models to compare 90-day confirmed disability accumulation events in people with exclusively non-disabling relapses within 2 years of RRMS diagnosis to those with no early relapses; and any early disabling relapses. Analyses were stratified by disease-modifying therapy (DMT) efficacy during follow-up. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> People who experienced non-disabling relapses within 2 years of RRMS diagnosis accumulated more disability than those with no early relapses if they were untreated ( n = 285 vs 4717; hazard ratio (HR) = 1.29, 95% confidence interval (CI) = 1.00–1.68) or given platform DMTs ( n = 1074 vs 7262; HR = 1.33, 95% CI = 1.15–1.54), but not if given high-efficacy DMTs ( n = 572 vs 3534; HR = 0.90, 95% CI = 0.71–1.13) during follow-up. Differences in disability accumulation between those with early non-disabling relapses and those with early disabling relapses were not confirmed statistically. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> This study suggests that early non-disabling relapses are associated with a higher risk of disability accumulation than no early relapses in RRMS. This risk may be mitigated by high-efficacy DMTs. Therefore, non-disabling relapses should be considered when making treatment decisions. </jats:p></jats:sec>